Breast cancer (BC), the most common invasive malignant tumor, has been the main cause of cancer death in women with a rising incidence. Unfortunately, approximately 30% of BC patients succumb to metastatic disease. The prognosis of patients with metastatic BC is poor due to lack of effective therapeutic options, and the survival time is about 2–4 years, highlighting the urgent need to understand and develop anti-metastatic therapies. Migration and invasion are the bases of cancer metastasis and the important steps in the progression and recurrence of BC. Inhibition of migration and invasion in BC is the current trend. Angiogenesis, the rapid increase in the formation of blood vessels, takes an active part in BC progression and metastasis. Furthermore, increased angiogenesis is correlated with decreased survival in BC patients. Targeting angiogenesis in cancer therapy is an appealing approach to inhibit the metastasis of BC. Although many drugs are approved for the treatment of cancer, they have various toxicities and side effects, which emphasize the urgency of developing more effective cancer drugs with minimal side effects.Astragalin (kaempferol-3-beta-D-glucoside) is a flavonoid existing in several edible and medicinal plants, such as persimmon, Morus alba L., Cuscuta chinensis, and Thesium chinense.

It has been confirmed that Astragalin has substantial pharmacological effects, including anti-inflammatory, anti-oxidant, neuroprotective, cardioprotective, anti-diabetic, and anti-cancer properties. Despite its various biological activities, the effect of Astragalin against BC is not well understood. In our study, we aimed to investigate the anti-tumor effect of Astragalin on the metastasis and angiogenesis of BC and elucidated the potential mechanisms.

visit for more articles at Journal of Heart and Cardiovascular Research

Kindly submit your article at  https://www.imedpub.com/submissions/heart-cardiovascular-research.html

Regards
Mishita
Jornal co-ordinator
Journal of Heart and Cardiovascular Research